Short Communication: Integrase Strand Transfer Inhibitors Drug Resistance Mutations in Puerto Rico HIV-Positive Individuals

Reduced efficacy of HIV-1 integrase inhibitors in patients with drug resistance mutations in reverse transcriptase

(2020) Mark J. Siedner et al.   Nature Communications

A systematic review of the genetic mechanisms of dolutegravir resistance

(2019) Soo-Yon Rhee et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Molecular Epidemiology of HIV-1 Virus in Puerto Rico: Novel Cases of HIV-1 Subtype C, D, and CRF-24BG

(2018) Pablo López et al.   AIDS RESEARCH AND HUMAN RETROVIRUSES

Prevalence of Primary Drug Resistance Against HIV-1 Integrase Inhibitors in Canada

(2018) Hezhao Ji et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Rare emergence of drug resistance in HIV-1 treatment-naïve patients receiving elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide for 144 weeks

(2018) Nicolas Margot et al.   JOURNAL OF CLINICAL VIROLOGY

Efficacies of Cabotegravir and Bictegravir against drug-resistant HIV-1 integrase mutants

(2018) Steven J. Smith et al.   Retrovirology

Strain-specific effect on biphasic DNA binding by HIV-1 integrase

(2018) Kyle J. Hill et al.   AIDS

A decade of viral mutations and associated drug resistance in a population of HIV-1+ Puerto Ricans: 2002–2011

(2017) Lycely del C. Sepúlveda-Torres et al.   PLoS One

HIV drug resistance against strand transfer integrase inhibitors

(2017) Kaitlin Anstett et al.   Retrovirology

Improving the Adherence to Antiretroviral Therapy, a Difficult but Essential Task for a Successful HIV Treatment—Clinical Points of View and Practical Considerations

(2017) Simona A. Iacob et al.   Frontiers in Pharmacology

Current status and prospects of HIV treatment

(2016) Tomas Cihlar et al.   Current Opinion in Virology

Effects of Raltegravir or Elvitegravir Resistance Signature Mutations on the Barrier to Dolutegravir ResistanceIn Vitro

(2015) Takahiro Seki et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

The Genetic Diversity and Evolution of HIV-1 Subtype B Epidemic in Puerto Rico

(2015) Pablo López et al.   International Journal of Environmental Research and Public Health

The Combined Anti-HIV-1 Activities of Emtricitabine and Tenofovir plus the Integrase Inhibitor Elvitegravir or Raltegravir Show High Levels of SynergyIn Vitro

(2014) Rima Kulkarni et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

COMET: adaptive context-based modeling for ultrafast HIV-1 subtype identification

(2014) Daniel Struck et al.   NUCLEIC ACIDS RESEARCH

Dolutegravir: clinical efficacy and role in HIV therapy

(2014) Alessandra Fantauzzi et al.   Therapeutic Advances in Chronic Disease

Impact of Primary Elvitegravir Resistance-Associated Mutations in HIV-1 Integrase on Drug Susceptibility and Viral Replication Fitness

(2013) Michael E. Abram et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Resistance to HIV Integrase Strand Transfer Inhibitors Among Clinical Specimens in the United States, 2009–2012

(2013) Christopher B. Hurt et al.   CLINICAL INFECTIOUS DISEASES

Next-Generation Integrase Inhibitors

(2013) Sharon L. Karmon et al.   DRUGS

Automated subtyping of HIV-1 genetic sequences for clinical and surveillance purposes: Performance evaluation of the new REGA version 3 and seven other tools

(2013) Andrea-Clemencia Pineda-Peña et al.   INFECTION GENETICS AND EVOLUTION

Broad Phenotypic Cross-Resistance to Elvitegravir in HIV-Infected Patients Failing on Raltegravir-Containing Regimens

(2012) Carolina Garrido et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Evolution of HIV integrase resistance mutations

(2012) Peter K. Quashie et al.   CURRENT OPINION IN INFECTIOUS DISEASES

Emerging patterns and implications of HIV-1 integrase inhibitor resistance

(2012) Anna Maria Geretti et al.   CURRENT OPINION IN INFECTIOUS DISEASES

The Activity of the Integrase Inhibitor Dolutegravir Against HIV-1 Variants Isolated From Raltegravir-Treated Adults

(2012) Mark R. Underwood et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Safety and Efficacy of Dolutegravir in Treatment-Experienced Subjects With Raltegravir-Resistant HIV Type 1 Infection: 24-Week Results of the VIKING Study

(2012) Joseph J. Eron et al.   JOURNAL OF INFECTIOUS DISEASES

In vitro resistance selections using elvitegravir, raltegravir, and two metabolites of elvitegravir M1 and M4

(2011) Nicolas A. Margot et al.   ANTIVIRAL RESEARCH

Cross-Resistance Profile Determination of Two Second-Generation HIV-1 Integrase Inhibitors Using a Panel of Recombinant Viruses Derived from Raltegravir-Treated Clinical Isolates

(2010) L. Van Wesenbeeck et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

In VitroAntiretroviral Properties of S/GSK1349572, a Next-Generation HIV Integrase Inhibitor

(2010) Masanori Kobayashi et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Primary mutations selected in vitro with raltegravir confer large fold changes in susceptibility to first-generation integrase inhibitors, but minor fold changes to inhibitors with second-generation resistance profiles

(2010) Olivia Goethals et al.   VIROLOGY

Pharmacokinetics and Safety of S/GSK1349572, a Next-Generation HIV Integrase Inhibitor, in Healthy Volunteers

(2009) S. Min et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Strand transfer inhibitors of HIV-1 integrase: Bringing IN a new era of antiretroviral therapy

(2009) Damian J. McColl et al.   ANTIVIRAL RESEARCH

Loss of Raltegravir Susceptibility by Human Immunodeficiency Virus Type 1 Is Conferred via Multiple Nonoverlapping Genetic Pathways

(2009) S. Fransen et al.   JOURNAL OF VIROLOGY